Chimpanzee adenovirus-mediated multiple gene therapy for age-related macular degeneration

Selena Wei-Zhang,Bohao Cui,Man Xing,Jiaojiao Liu,Yingying Guo,Kai He,Tinghui Bai,Xue Dong,Yi Lei,Wei Zhou,Hui Zhou,Shengnan Liu,Xiaohong Wang,Dongming Zhou,Hua Yan
DOI: https://doi.org/10.1016/j.isci.2023.107939
IF: 5.8
2023-10-01
iScience
Abstract:Neovascular age-related macular degeneration AMD (nAMD) is characterized by choroidal neovascularization (CNV) and could lead to irreversible blindness. However, anti-vascular endothelial growth factor (VEGF) therapy has limited efficacy. Therefore, we generated a chimpanzee adenoviral vector (AdC68-PFC) containing three genes, pigment endothelial-derived factor (PEDF), soluble fms-like tyrosine kinase-1 (sFlt-1), and soluble forms of CD59 (sCD59), to treat nAMD. The results showed that AdC68-PFC mediated a strong onset of PEDF, sFlt-1, and sCD59 expression both <i>in vivo</i> and <i>in vitro</i>. AdC68-PFC showed preventive and therapeutic effects following intravitreal (IVT) injection in the laser-induced CNV model and very low-density lipoprotein receptor-deficient (<i>Vldlr</i><sup><i>-/-</i></sup>) mouse model. <i>In vitro</i> assessment indicated that AdC68-PFC had a strong inhibitory effect on endothelial cells. Importantly, the safety test showed no evidence of <i>in vivo</i> toxicity of adenovirus in murine eyes. Our findings suggest that AdC68-PFC may be a long-acting and safe gene therapy vector for future nAMD treatments.
multidisciplinary sciences
What problem does this paper attempt to address?